PFBT
VERV

Parkside Financial Bank & Trust’s Verve Therapeutics VERV Stock Holding History

Parkside Financial Bank & Trust’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45
Closed -$506 – 2818
2025
Q2 		$506 Sell
45
-25
-36% -$143 ﹤0.01% 2549
2025
Q1 		$318 Buy
+70
New +$469 ﹤0.01% 2618

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Parkside Financial Bank & Trust's VERV Position: Q3 2025 in Review

Parkside Financial Bank & Trust sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 45 shares — an estimated $506 sold.

Parkside Financial Bank & Trust first reported a position in VERV in Q1 2025 and held it in 2 quarters. The position peaked at $506 in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Parkside Financial Bank & Trust reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Parkside Financial Bank & Trust sold 45 Verve Therapeutics shares in Q3 2025, an estimated $506.
  • Parkside Financial Bank & Trust first reported a position in Verve Therapeutics in Q1 2025 and held it in 2 quarters.
  • Parkside Financial Bank & Trust's Verve Therapeutics position peaked at $506 in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q3 2025, filed 30 Oct 2025.